Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Myocardial Protection in Pediatric Cyanotic CHD Surgery
NCT05300802Phase 3Completed
- Sponsor
- National Cardiovascular Center Harapan Kita
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexmedetomidine in cyanotic congenital heart disease (CCHD), sponsored by National Cardiovascular Center Harapan Kita. Started Dec 2021; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
cyanotic congenital heart disease (CCHD)
Beyond the preview
Go deeper on NCT05300802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300802.